Lumigan 0.01% Eye Drop

Lumigan 0.01% is AbbVie's (formerly Allergan's) bimatoprost 0.1 mg/mL eye drop for lowering raised pressure inside the eye in open-angle glaucoma and ocular hypertension. We sell the Indian pack, which the PharmEasy and Truemeds listings give as a 3 mL bottle with Ireland as the country of origin; PharmEasy names Allergan India Pvt Ltd and Truemeds lists AbbVie Therapeutics India as the company. Packs of 3 and 6 bottles cost from $12.67 a bottle (about $4.22 per mL) before shipping.

Glaucoma needs an eye doctor. The US National Eye Institute says it usually has no symptoms at first, and that treatment cannot undo vision already lost, though early treatment can often stop the damage. Eye drops only help if the diagnosis is right and the pressure is checked to confirm they are working. Use Lumigan only after an eye examination and with regular pressure checks by an ophthalmologist or optometrist. Do not start it, or switch to it from another drop, on your own.

This page covers the price per bottle, how the Indian pack compares with US Lumigan and generic bimatoprost, the 0.01% and 0.03% strengths, how to use the drops, side effects, when to get urgent help, who should not use it, and delivery. Clinical figures come from the US prescribing information for Lumigan 0.01% and the UK product information for Lumigan 0.1 mg/ml, listed at the end.

Lumigan 0.01% at a glance

Price per bottle

Prices below are as of October 2026; the pack selector shows the current price.

The 6 bottle pack is cheaper per bottle before shipping as well as after it. Both packs are under the $149 free shipping threshold, so each order carries the flat $25. The last column is our own arithmetic: the UK leaflet says a 3 mL bottle is enough for 4 weeks and should be thrown away 4 weeks after opening, so one bottle a month is the rule we used. Check the expiry date on the cartons before you buy a large supply.

Compared with US Lumigan and generic bimatoprost

The US figures are what US pharmacies paid per mL in the Medicaid NADAC survey (rates effective 23 September 2026, latest file 14 October 2026), multiplied by each bottle size. They are acquisition costs, not shelf prices, and the price at the counter is higher. The US Lumigan 0.03% brand is listed by the FDA as discontinued, with a Federal Register determination that it was not withdrawn for safety or effectiveness reasons; generic 0.03% drops are still sold. If you are in the US and have a prescription or insurance, compare your copay and local cash prices for generic bimatoprost before ordering from abroad.

We have not found a published study comparing the Indian Lumigan pack with the US or UK pack. The UK leaflet names Allergan Pharmaceuticals Ireland in Westport as the manufacturer, and PharmEasy gives the same address for the Indian pack, but we have not seen the strip or carton ourselves.

Which strength to choose

We stock two Lumigan strengths. They are not interchangeable without your eye doctor's agreement.

In a 12 month randomised, double-masked trial of 561 patients (Katz 2010, PMID 20346780), bimatoprost 0.01% lowered eye pressure as well as 0.03%, with differences in mean pressure under 0.9 mmHg throughout. Treatment-related adverse events were significantly less common with 0.01%, and a moderate to severe increase in eye redness occurred in 3.2% on 0.01% against 9.1% on 0.03%.

Do not use two bimatoprost products together, and do not add Careprost, Latisse or a lash serum to Lumigan. The UK label says more frequent exposure of the eye to bimatoprost may decrease the pressure-lowering effect, and that the effect of prostaglandin analogues may be reduced when they are used with other prostaglandin analogues. Lumigan 0.01% is not a lash product: the eyelash trials behind Latisse used 0.03% applied to the lid margin. See Lumigan vs Careprost for the full comparison.

How to use Lumigan 0.01%

1. Wash your hands. If you wear soft contact lenses, take them out first.
2. Tilt your head back and gently pull down the lower eyelid to make a small pocket.
3. Turn the bottle upside down and squeeze one drop into each eye that needs treatment. Do not let the tip touch your eye, eyelid, fingers or any other surface.
4. Let go of the lid and close your eye for 30 seconds. Wipe off any drop that runs onto your cheek.
5. Put the cap back on straight away. Wait 15 minutes before putting contact lenses back in.

• Once a day, in the evening. The US label says it "should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect."
• Other eye drops: leave at least 5 minutes between Lumigan and any other eye drop.
• Missed dose: the UK leaflet says use a single drop as soon as you remember, then go back to your usual routine. Do not use a double dose.
• Too many drops: the UK leaflet says this is unlikely to cause serious harm; put the next dose in at the usual time.
• Do not stop on your own: the UK leaflet says the pressure inside the eye may go up if you stop, so talk to your doctor first.
• Skin contact: hair can grow where the solution repeatedly touches the skin (UK label), so wipe away runoff.
• Driving: wait until any blurring after the drop has cleared.

The UK leaflet says to throw the bottle away 4 weeks after first opening, even if drops are left, to prevent infection. The US label lets an opened bottle be used until the expiry date, so follow the instruction printed on your Indian carton, and write the opening date on the box. Our guide to glaucoma eye drop types explains how prostaglandin drops fit with the other classes.

Groups who need extra care

• Children and teenagers: the US label says use below the age of 16 "is not recommended" because of possible safety concerns about increased pigmentation with long-term use. The UK label says safety and efficacy under 18 have not been established, and the UK leaflet says it should not be used under 18.
• Dry eye or a damaged cornea: the UK label notes that Lumigan 0.1 mg/ml contains 200 ppm benzalkonium chloride, four times the amount in the 0.3 mg/ml drop, and says to use it with caution in dry eye, where the cornea may be compromised, and in people using several preserved eye drops, with monitoring during long use.
• Inflammation inside the eye: the US label says caution should be used in active intraocular inflammation such as uveitis, because prostaglandin analogues may make it worse. The UK label adds caution after significant viral eye infections such as herpes simplex.
• Risk of macular oedema: caution if you have had cataract surgery without a lens implant (aphakia), have a lens implant with a torn posterior capsule, or have other known risk factors (US label 5.4).
• Asthma, COPD or other breathing problems: the UK label reports post-marketing cases of asthma, worsening asthma or COPD and shortness of breath, and says to use it with caution.
• Low heart rate or low blood pressure: the UK label says caution, after a limited number of reports of slow heart rate or low blood pressure with the 0.3 mg/ml drop.
• Liver or kidney problems: not studied in kidney impairment or moderate to severe liver impairment; the UK label says caution.
• Other glaucoma types: the UK label says Lumigan has not been studied in inflammatory, neovascular, angle-closure, congenital or narrow-angle glaucoma.
• Pregnancy: the US label says use it "only if the potential benefit justifies the potential risk to the fetus"; the UK label says it "should not be used during pregnancy unless clearly necessary".
• Breastfeeding: the UK leaflet says you should not breastfeed while using Lumigan. The UK SmPC says to decide between stopping breastfeeding or stopping treatment. The US label says to weigh the benefits of breastfeeding against the mother's need for the drug.

Side effects

In the 12 month US study of bimatoprost 0.01%, the most common adverse reaction was red eyes (conjunctival hyperaemia), in 31% of patients, and about 1.6% stopped treatment because of it. The UK label gives 29% from its 12 month study, mostly trace to mild. Other reactions in 1% to 4% of patients in the US study were:

The label also warns about changes that can last:

• Brown darkening of the iris. The US label says it is "likely to be permanent" and may not be noticeable for months to years. The UK label gives 0.5% at 12 months with 0.01%. Treatment can continue, but you should be examined regularly.
• Darker eyelid skin and longer, thicker, darker lashes in the treated eye, which can make the eyes look different if only one is treated. The US label says lash changes are usually reversible after stopping, while darker eyelid skin has been reversible only in some patients; the UK leaflet says these changes may be permanent.
• Fat loss around the eye (prostaglandin analogue periorbitopathy): a deeper lid crease, a sunken eye, a drooping or retracted lid. The UK label lists it as very common, says it can start as early as one month and may affect the field of vision, and says changes have been partially or fully reversible after stopping or switching.
• Macular oedema (swelling at the back of the eye that can blur vision) and inflammation inside the eye have been reported.
• Eye infection from a contaminated bottle tip. The US label says serious damage to the eye and loss of vision may result from using contaminated solutions.

Reports after approval include dry eye, discharge, a feeling of something in the eye, sensitivity to light, watering, headache, dizziness, high blood pressure, shortness of breath and asthma-like symptoms, and allergic reactions of the eye or skin. Our Lumigan glaucoma guide covers them in more depth.

When to get urgent help

• Sudden eye pain, a sudden drop in vision or any new change in your sight.
• Signs of an eye infection, such as a painful red eye, discharge or sensitivity to light, or any injury to the eye.
• Swelling of the eyelids, a rash on the eyelids or around the eye, or marked redness and itching after a drop: signs of an allergic reaction. Stop the drops and get medical advice.

The US label tells patients to seek their doctor's advice immediately about continuing Lumigan if they develop an eye condition such as trauma or infection, have eye surgery, or develop any eye reaction, particularly conjunctivitis and eyelid reactions. Tell any doctor treating you that you use bimatoprost eye drops.

Who should not use Lumigan 0.01%

Never use it (contraindications):

• if you are allergic to bimatoprost or any ingredient of the drops (US label section 4, UK label 4.3);
• if you have had to stop an eye drop because of a reaction to the preservative benzalkonium chloride (UK label 4.3).

Not recommended (US label 8.4):

• children under 16. The UK leaflet says it should not be used under 18.

Talk to your eye doctor first (label cautions): the groups listed above, including uveitis or a past herpes eye infection, macular oedema risk, dry eye or corneal problems, asthma or COPD, low heart rate or blood pressure, pregnancy and breastfeeding. Also tell your doctor about every other eye drop you use, especially other prostaglandin drops.

Prescription and legal status

Bimatoprost glaucoma drops are prescription medicines in the US ("Rx only" on the Lumigan label), the UK (prescription only medicine), Canada (Lumigan RC, prescription) and Australia (Lumigan 0.03% is Schedule 4, prescription only). The PharmEasy and Truemeds listings in India also mark Lumigan 0.01% as prescription required. The Indian pack is not the pack approved by the FDA, the MHRA or Health Canada, and in the US the FDA says personal importation of unapproved medicines is illegal in most circumstances. Whatever the rules where you live, glaucoma needs a diagnosis and regular eye pressure and optic nerve checks; we recommend buying Lumigan only to continue a treatment your eye doctor has prescribed. Our guide to buying eye drops online covers this in more detail.

Buying genuine Lumigan

The MHRA warns: "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have." The Indian pack is not authorised for sale in the UK, so this applies to it. The MHRA also advises: "Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo." When your order arrives, check that the carton names Allergan or AbbVie and shows bimatoprost 0.01%, a batch number and an expiry date, that the seal on the bottle neck is unbroken, and that the solution is clear and colourless. These checks cannot prove a bottle is genuine, because counterfeiters copy packaging. If your eye pressure readings rise after switching supply, tell your eye doctor. If a batch causes unusual symptoms, stop using it, seek medical advice, and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.

Delivery

We ship Lumigan 0.01% to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days to most countries, so order well before your current bottle runs out: missing doses lets eye pressure rise. The US label allows storage between 2°C and 25°C, so the drops do not need a fridge. Shipping costs a flat $25 on orders under $149 and is free from $149. See our shipping page for times by region.

Related guides and products

• Lumigan eye drops for glaucoma: uses, dosage, side effects and cost
• Lumigan vs Careprost: same bimatoprost, different strengths
• Glaucoma eye drops: every type explained
• Latanoprost eye drops guide
• Buying eye drops from an online pharmacy

Other glaucoma drops we stock: Lumigan 0.03%, Careprost (bimatoprost 0.03%), Careprost Plus (bimatoprost with timolol), Latoprost (latanoprost) and Combigan (brimonidine with timolol). Changing from one to another is a decision for your eye doctor.

Sources

• LUMIGAN (bimatoprost ophthalmic solution) 0.01%, US prescribing information, AbbVie, revised June 2024, sections 1, 2, 4, 5, 6, 8, 11, 14, 16 and 17. DailyMed
• LUMIGAN 0.1 mg/ml eye drops, solution, UK Summary of Product Characteristics (revised 1 April 2022) and patient leaflet (revised February 2022), AbbVie Ltd. emc
• Drugs@FDA: LUMIGAN 0.01%, NDA 022184, approved 31 August 2010; LUMIGAN 0.03%, NDA 021275, discontinued.
• Health Canada Drug Product Database: LUMIGAN RC (bimatoprost 0.01%), DIN 02324997, marketed, prescription.
• healthdirect Australia: Lumigan 0.03% eye drops, ARTG 80657, Schedule 4.
• Katz LJ et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol 2010;149(4):661-671.e1. PMID 20346780.
• Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), 2026 file, rates effective 23 September 2026 (file dated 14 October 2026). data.medicaid.gov
• MHRA warning on medicines bought online, 13 February 2026.
• National Eye Institute. Glaucoma. NEI
• US Food and Drug Administration. Personal Importation. FDA

This page is for information and is not medical advice. Lumigan is a prescription medicine for glaucoma; use it only under the care of an eye doctor.